Thesis
AX-0810 posts clean Phase 1 target engagement with Lilly investment and fresh capital, but biliary atresia Phase 2 data won't arrive until mid-2028
ProQR's Axiomer RNA-editing platform produced its first human proof-of-concept with AX-0810, an NTCP modulator for cholestatic liver disease, showing 8-fold bile acid elevation against a 2-fold threshold across two dose cohorts. Whether the thesis pays off hinges on whether that pharmacodynamic signal translates to clinical benefit in a pediatric biliary atresia trial, where single-arm investigator-initiated data from China will face generalizability scrutiny. A $50M raise and a Lilly strategic investment extend runway past the interim analysis, but that data won't arrive until mid-2028, leaving investors exposed to two years of binary uncertainty.
Focus
AX-0810 Phase 2 first interim analysis data readout
mid-2028
Bull
A positive interim analysis would show statistically meaningful reduction in serum bile acids or liver fibrosis markers in pediatric biliary atresia patients, demonstrating that NTCP modulation achieved in healthy volunteers translates to disease modification in a surgically-treated pediatric population. This would validate the Axiomer platform in a rare pediatric indication with high unmet need, likely triggering additional Lilly milestones, potential regulatory fast-track designations, and a substantial re-rating of the stock.
Bear
The most likely failure modes are lack of efficacy translation from healthy volunteer pharmacology to a structurally damaged pediatric biliary system post-Kasai portoenterostomy, where residual bile flow and hepatic architecture vary widely; a heterogeneous patient population with inconsistent baseline disease severity could obscure a true treatment signal. Safety concerns specific to pediatric dosing — particularly given the 8-week half-life — could also complicate the risk-benefit profile and force protocol amendments that delay the program further.
Unlock the full thesis for PRQR.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.